Anti-CTLA-8 / IL-17a Reference Antibody (vunakizumab)

  • Product Code: 139984
Molecular Weight: Molecular Formula:
EC Number: MDL Number:
Melting Point: Boiling Point:
Density: Storage Condition: -20℃
Product Description: Used in the treatment of autoimmune diseases such as psoriasis, psoriatic arthritis, and ankylosing spondylitis. It works by neutralizing interleukin-17A (IL-17A), a key cytokine involved in inflammatory pathways, thereby reducing inflammation and disease symptoms. This antibody helps decrease skin lesions in moderate to severe plaque psoriasis and improves joint function and quality of life in patients with chronic inflammatory conditions. It is administered via subcutaneous injection and is part of a class of biologic therapies targeting specific components of the immune system.
Sizes / Availability / Pricing:
Size Availability Price Quantity
50μg 10-20 days ฿4,980.00
+
-
Anti-CTLA-8 / IL-17a Reference Antibody (vunakizumab)
Used in the treatment of autoimmune diseases such as psoriasis, psoriatic arthritis, and ankylosing spondylitis. It works by neutralizing interleukin-17A (IL-17A), a key cytokine involved in inflammatory pathways, thereby reducing inflammation and disease symptoms. This antibody helps decrease skin lesions in moderate to severe plaque psoriasis and improves joint function and quality of life in patients with chronic inflammatory conditions. It is administered via subcutaneous injection and is part of a class of biologic therapies targeting specific components of the immune system.
Mechanism -
Appearance -
Longevity -
Strength -
Storage -
Shelf Life -
Allergen(s) -
Dosage (Range) -
Dosage (Per Day) -
Mix Method -
Heat Resistance -
Stable in pH range -
Solubility -
Product Types -
INCI -

Purchase History for

Loading purchase history...

Cart

No products

Subtotal: ฿0.00
฿0.00 Total :

The availability date depends on real-time stock, and any changes after payment will be notified within 30 minutes
You can choose the delivery date on the next page